clinical-gastroenterology-digestive-diseases2017-tracks

24 / 24

Volume 7, Issue 6 (Suppl) J Gastrointest Dig Syst, an open access journal
ISSN: 2161-069X
Page 50
December 07-08, 2017 Madrid, Spain
&
13th International Conference on Clinical Gastroenterology & Hepatology
2nd International Conference on Digestive Diseases
CO-ORGANIZED EVENT
AKT2 expression and two years overall survivor in colorectal cancer: A retrospective cohort study
Caroline Saad Vargas
State University of Ponta Grossa, Brazil
Statement of the Problem: Colorectal cancer (CRC) is one of the most important cancers. There is a great effort to understand
the molecular involvement to predict and counterbalance the odds of metastatic disease. The proto-oncogene serine/threonine
kinase(AKT2) stood out among the studies. The role of AKT isoforms as a whole is already linked to cell proliferation, glucose
uptake, metabolism, angiogenesis and radiation and drug response. The researches with AKT2 have linked its expression with
advanced tumors and metastatic CRC. However, there is a lack of studies comparing the AKT2 expression and overall survivor
(OS) in CRC patients yet. This study intends to evaluate the relation between AKT2 expression and two years OS among
patients with CRC.
Methods: 140 patients with CRC diagnosed between 2010 and 2015 in a city in Paraná state, Brazil were enrolled for this study.
Primary tumor samples were obtained and analyzed through immunohistochemistry for expression of AKT2.The clinical data
was retrospective collected frommedical records. Shapiro-Wilk test found a non-Gaussian distribution, hence Mann-Whitney
test was conducted. The authors defined significant a P>0.05.
Findings: 96 patients (68.6%) had a positive two years OS. Forty-four (31.4%) had a confirmation of death in the period. The
survivors group had an AKT2 expression varying between 0.6 and 60.3, 95% confidence interval (CI) of 12.2 and 20.8 and a
median of 17.2. The death group positivity was between 0.9 and 58.9, the 95% CI discreetly higher, between 14.8 and 29.8 and
a 21.8 median.
Conclusion: The 95% CI and medians obtained were higher among the patients with the death outcome in two years. However,
the statistical analysis found no significance in AKT2 expression among the groups (P=0.2378). Therefore, the results suggest
that there is no correlation between the marker expression and two years OS in CRC patients. However, it is important to
continue the researches with the AKT2 to check for different results when comparing specific groups of patients.
Recent Publications
1. Agarwal E, Brattain M G and Chowdhury S (2013) Cell survival and metastasis regulation by Akt signalling in
colorectal cancer. Cell Signal 25:1711-1719.
2. Agarwal E, Robb CM, Smith L M, Brattain MG, Wang J, Black J D and Chowdhury S (2017) Role of Akt2 in regulation
of metastasis suppressor 1 expression and colorectal cancer metastasis. Oncogene 36:3104-3118.
3. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt J A, Chan A T, Giovannucci E, Fuchs C S and Ogino S (2011)
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717
colorectal cancers. Cancer 117:1399:1408.
4. Ding Z, Xu F, Li G, Tang J, Tang Z, Jiang P,WuH (2014) Knockdown of Akt2 expression by ShRNA inhibits proliferation,
enhances apoptosis, and increases chemosensitivity to paclitaxel in human colorectal cancer cells. Cell Biochemistry
and Biophysics 71:383-388.
5. Sahlberg S H, Gustafsson A S, Pendekanti P N, Glimelius B and Stenerlow B (2014) The influence of AKT isoforms on
radiation sensitivity and DNA repair in colon cancer cell lines. Tumor Biology 35:3525-3534.
Biography
Caroline Saad Vargas is a Gastroenterologist, Endoscopist and Assistant Professor at State University of Ponta Grossa. She has her expertise in Advanced
Endoscopy, Eosinophilic esophagitis and she is currently working on inflammatory colorectal cancer pathways on her PhD.
Caroline Saad Vargas, J Gastrointest Dig Syst 2017, 7:6(Suppl)
DOI: 10.4172/2161-069X-C1-058